Trial · NCT07886151
Prophylactic Ondansetron for Preventing Spinal Anesthesia-Induced Hypotension in Elective Cesarean Section
NCT07886151, Phase 4, Completed, Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Prophylactic Ondansetron for Preventing Spinal Anesthesia-Induced Hypotension in Elective Cesarean Section. Trials, record NCT07886151. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07886151
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Prophylactic Ondansetron for Preventing Spinal Anesthesia-Induced Hypotension in Elective Cesarean Section
- NCT number
- NCT07886151
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 96 participants, actual
- Lead sponsor
- Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital
- Conditions
- Hypotension, Spinal Anesthesia, Cesarean Section
- Interventions
- Ondansetron, Placebo (0.9% Sodium Chloride)
- First posted
- 2026-10-21
- Last updated
- 2026-10-21
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence of Spinal Anesthesia-Induced Hypotension | From intrathecal injection until the end of surgery (up to 60 minutes) | Percentage of participants who develop hypotension, defined as a mean arterial pressure (MAP) below 65 mmHg or a decrease of 20% or more from baseline MAP at any measurement time after spinal anesthesia. MAP is recorded at baseline and at 3, 6, 9, 12, 15, 20, 25, 30 and 35 minutes after spinal anesthesia. |
| Secondary | Total Ephedrine Consumption | From intrathecal injection until the end of surgery (up to 60 minutes) | Total dose (mg) of intravenous ephedrine administered to treat hypotension (10 mg boluses, repeated as needed). |
| Secondary | Mean Arterial Pressure Over Time | Baseline and 3, 6, 9, 12, 15, 20, 25, 30 and 35 minutes after spinal anesthesia, and postoperatively | Mean arterial pressure (mmHg) measured non-invasively at baseline (before spinal anesthesia) and at 3, 6, 9, 12, 15, 20, 25, 30 and 35 minutes after spinal anesthesia, and postoperatively. |
| Secondary | Heart Rate and Incidence of Bradycardia | Baseline and 3, 6, 9, 12, 15, 20, 25, 30 and 35 minutes after spinal anesthesia, and postoperatively | Heart rate (beats/min) at the same time points as blood pressure; bradycardia is defined as heart rate below 50 beats/min, and the number of participants requiring 0.5 mg IV atropine is recorded. |
| Secondary | Incidence of Postspinal Shivering | From intrathecal injection until the end of surgery (up to 60 minutes) | Percentage of participants with clinically significant shivering, defined as grade 2 or higher on the five-point Crossley and Mahajan shivering scale. |
| Secondary | Incidence of Intraoperative Nausea and Vomiting | From intrathecal injection until the end of surgery (up to 60 minutes) | Percentage of participants experiencing at least one episode of nausea or vomiting during surgery. |
| Secondary | Neonatal Apgar Scores | 1 and 5 minutes after delivery | Apgar scores of the newborn at 1 and 5 minutes after delivery (scale 0-10; higher scores indicate better neonatal condition). |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07886151
GET https://conductscience.org/api/trials/v1/NCT07886151/registered